Report Overview

The Hepatitis Drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hepatis is an inflammatory condition of liver commonly caused by a viral infection or due to certain medications or excessive alcohol consumption. There are five strains of hepatitis viruses namely Hepatitis A, B, C, D, or E Virus. Hepatitis can be short term (Hepatis A) or can cause chronic illness (Hepatitis B and C). Untreated chronic hepatitis B infection can result in liver cirrhosis and eventually death. Health care workers, intravenous drug users, commercial sex workers and men who have sex with men (MSM) are high risk groups for Hepatitis B virus (HBV) infection. Due to similar routes of transmission, Human Immunodeficiency Virus (HIV) infected individuals are also at high risk for Hepatitis B infection. The prevalence of HBV infection in Kenya is estimated to be between 1% to 5%, although rates among specific high-risk populations (HIV co-infected, drug abusers, jaundiced patients seeking medical care) are much higher. There is high Hepatitis C (HCV) infection prevalence among cohort of drug users (22.2%) as compared to that of the general population, which is estimated to be 0.2-0.9%.



Market Drivers

The market is majorly driven by the high prevalence rate of Hepatitis B infection in Kenya. The risk of Hepatitis B infection is greatly increased due to the high prevalence of HIV/AIDs in Kenya as HIV and HBV share common mode of transmissions.

Increase in substance abuse, alcohol consumption, involving in unprotected sex and other risk factors among adolescents in Kenya are leading to high incidence of HBV infections.

Increase in Government initiatives like screening for hepatitis among high-risk populations and providing clinical care for patients who have tested positive is expected to fuel growth in the hepatitis drug market.

However, the side effects caused by several Drug are restraining market growth. The outbreak of COVID-19 has decreased diagnosis, screening and follow-up of patients suffering from hepatitis which has negative outcomes of health in patients with hepatis.